Dare Bioscience, Inc. current report, 10 September 2026

Dare Bioscience, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Dare Bioscience, Inc. on September 10, 2026. The report addresses a corporate governance amendment approved by the Board of Directors effective immediately.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change to the company's bylaws and does not contain financial performance data.

Material Changes

The Board of Directors approved an amendment to the Third Amended and Restated By-Laws. The primary change reduces the quorum requirement for all stockholder meetings:

  • Previous Requirement: Holders of a majority in voting power of issued and outstanding shares entitled to vote.
  • New Requirement: Holders of at least one-third of the voting power of issued and outstanding shares entitled to vote.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items. The document is limited to the procedural amendment of the bylaws.

Key Facts for Investor Verification

  • Verify the effective date of the bylaw amendment (September 10, 2026).
  • Confirm the new quorum threshold is set at one-third of voting power.
  • Review Exhibit 3.1 for the full legal text of the amendment.
  • Note that this filing contains no financial results or operational updates.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.